Not Yet RecruitingPhase 2

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

France40 participantsStarted 2026-03

Plain-language summary

This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-80 years; * meeting clinical criteria for "possible" AE with identified antibodies; * newly diagnosed with symptoms \<6 months; * no second-line immunosuppressive treatment; * high or mixed TSPO binding affinity phenotype. Exclusion Criteria: * Pregnant women; * contraindications to MRI; * known allergic reaction to \[18F\]-DPA-714; legal protection measure; * paraneoplastic syndrome following immune checkpoint inhibitor therapy.

What they're measuring

binding potential (BP) in AE patients

Timeframe: Baseline

Trial details

NCT IDNCT07488117

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06

Contact for this trial

Marie Rafiq, MD

+33 561779491 rafiq.m@chu-toulouse.fr

View on ClinicalTrials.gov More Autoimmune Encephalitis (AE) trials